JP2013518130A5 - - Google Patents

Download PDF

Info

Publication number
JP2013518130A5
JP2013518130A5 JP2012551333A JP2012551333A JP2013518130A5 JP 2013518130 A5 JP2013518130 A5 JP 2013518130A5 JP 2012551333 A JP2012551333 A JP 2012551333A JP 2012551333 A JP2012551333 A JP 2012551333A JP 2013518130 A5 JP2013518130 A5 JP 2013518130A5
Authority
JP
Japan
Prior art keywords
bendamustine
long
term storage
containing composition
aqueous liquid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012551333A
Other languages
English (en)
Japanese (ja)
Other versions
JP5795600B2 (ja
JP2013518130A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/022958 external-priority patent/WO2011094565A1/en
Publication of JP2013518130A publication Critical patent/JP2013518130A/ja
Publication of JP2013518130A5 publication Critical patent/JP2013518130A5/ja
Application granted granted Critical
Publication of JP5795600B2 publication Critical patent/JP5795600B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012551333A 2010-01-28 2011-01-28 ベンダムスチンの製剤 Expired - Fee Related JP5795600B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29910010P 2010-01-28 2010-01-28
US61/299,100 2010-01-28
PCT/US2011/022958 WO2011094565A1 (en) 2010-01-28 2011-01-28 Formulations of bendamustine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015160351A Division JP6133943B2 (ja) 2010-01-28 2015-08-17 ベンダムスチンの製剤

Publications (3)

Publication Number Publication Date
JP2013518130A JP2013518130A (ja) 2013-05-20
JP2013518130A5 true JP2013518130A5 (cg-RX-API-DMAC10.html) 2014-03-13
JP5795600B2 JP5795600B2 (ja) 2015-10-14

Family

ID=44309429

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012551333A Expired - Fee Related JP5795600B2 (ja) 2010-01-28 2011-01-28 ベンダムスチンの製剤
JP2015160351A Active JP6133943B2 (ja) 2010-01-28 2015-08-17 ベンダムスチンの製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015160351A Active JP6133943B2 (ja) 2010-01-28 2015-08-17 ベンダムスチンの製剤

Country Status (16)

Country Link
US (17) US8609707B2 (cg-RX-API-DMAC10.html)
EP (3) EP3895694A1 (cg-RX-API-DMAC10.html)
JP (2) JP5795600B2 (cg-RX-API-DMAC10.html)
CA (1) CA2787568C (cg-RX-API-DMAC10.html)
CY (2) CY1118769T1 (cg-RX-API-DMAC10.html)
DK (2) DK3158991T3 (cg-RX-API-DMAC10.html)
ES (2) ES2609106T5 (cg-RX-API-DMAC10.html)
HR (2) HRP20161771T4 (cg-RX-API-DMAC10.html)
HU (2) HUE054836T2 (cg-RX-API-DMAC10.html)
LT (2) LT3158991T (cg-RX-API-DMAC10.html)
PL (2) PL2528602T5 (cg-RX-API-DMAC10.html)
PT (2) PT3158991T (cg-RX-API-DMAC10.html)
RS (2) RS55491B2 (cg-RX-API-DMAC10.html)
SI (2) SI3158991T1 (cg-RX-API-DMAC10.html)
SM (3) SMT202100348T1 (cg-RX-API-DMAC10.html)
WO (1) WO2011094565A1 (cg-RX-API-DMAC10.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011094565A1 (en) 2010-01-28 2011-08-04 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
US20120237492A1 (en) 2011-02-18 2012-09-20 Kythera Biopharmaceuticals, Inc. Treatment of submental fat
US20130210878A1 (en) * 2012-01-24 2013-08-15 Innopharma, Inc. Bendamustine compositions and methods therefore
CA2864118A1 (en) * 2012-02-14 2013-08-22 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
HRP20230276T1 (hr) * 2012-03-20 2023-04-28 Eagle Pharmaceuticals, Inc. Tekući pripravci bendamustina za uporabu u postupku liječenja stanja koja reagiraju na bendamustin kod pacijenata kojima za primjenu trebaju reducirani volumeni
ES2972227T3 (es) * 2012-03-20 2024-06-11 Eagle Pharmaceuticals Inc Formulaciones de bendamustina
CN109953954A (zh) 2013-08-27 2019-07-02 V·沃道里斯 苯达莫司汀医药组合物
HK1220632A1 (zh) * 2013-09-20 2017-05-12 参天制药株式会社 含有聚乙二醇的组合物
WO2015054550A1 (en) * 2013-10-11 2015-04-16 Luitpold Pharmaceuticals, Inc. Bendamustine pharmaceutical compositions
CA2941632C (en) 2014-03-13 2023-10-24 Vasilios VOUDOURIS Bendamustine solid dispersions and continuous infusion
WO2016005995A2 (en) * 2014-07-10 2016-01-14 Leiutis Pharmaceuticals Pvt. Ltd. Glycol free stable liquid compositions of bendamustine
US9603930B2 (en) 2014-12-04 2017-03-28 Navinta, Llc Liquid bendamustine formulation
US20170119794A1 (en) * 2015-11-04 2017-05-04 Kythera Biopharmaceuticals, Inc. Treatments of accumulated fat with deoxycholic acid and salts thereof
US11826466B2 (en) 2016-08-31 2023-11-28 Navinta, Llc Bendamustine solution formulations
US10905677B2 (en) 2016-08-31 2021-02-02 Navinta, Llc Bendamustine solution formulations
JP7464995B2 (ja) * 2018-03-29 2024-04-10 プロジェクト ファーマシューティクス ゲーエムベーハー 液体薬学的製剤
EP3836921B1 (en) * 2018-08-17 2025-10-08 Hospira Australia Pty Ltd Liquid bendamustine pharmaceutical compositions
US11730815B2 (en) 2018-11-26 2023-08-22 Good Health, Llc Stable liquid pharmaceutical compositions comprising bendamustine
JP2020090481A (ja) * 2018-11-27 2020-06-11 日本化薬株式会社 ベンダムスチンを含有する溶液製剤
JP7235288B2 (ja) * 2019-01-07 2023-03-08 コーアイセイ株式会社 ベンダムスチンの液体製剤
WO2020170104A1 (en) * 2019-02-18 2020-08-27 Shilpa Medicare Limited Liquid bendamustine parenteral compositions
WO2021161876A1 (ja) * 2020-02-10 2021-08-19 富士フイルム株式会社 ベンダムスチン液剤
CA3145107A1 (en) * 2020-04-09 2021-10-14 Yue Jing Bendamustine and cyclodextrin composition and use thereof
WO2023067188A1 (en) 2021-10-22 2023-04-27 Project Pharmaceutics Gmbh Liquid pharmaceutical formulation
GB202118175D0 (en) 2021-12-15 2022-01-26 Arecor Ltd Novel composition
US11707450B1 (en) 2022-03-03 2023-07-25 Slayback Pharma Llc Stable pharmaceutical compositions of bendamustine

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE159289C (cg-RX-API-DMAC10.html) 1903-10-08 1905-03-16
DE152989C (cg-RX-API-DMAC10.html)
DE80967C (cg-RX-API-DMAC10.html)
US4071620A (en) 1977-01-10 1978-01-31 American Home Products Corporation Stabilization of oxygen sensitive dose forms
DD152989A1 (de) 1980-09-11 1981-12-16 Klaus Kunze Anordnung zur korrektur von soll-und istwerten
DD159289A1 (de) * 1981-06-01 1983-03-02 Uwe Olthoff Verfahren zur herstellung stabiler injektionsloesungen von n-lostverbindungen
DE3446873A1 (de) * 1984-12-21 1986-07-10 Merckle Gmbh Fluessige diclofenac-zubereitungen
US5204335A (en) 1986-10-31 1993-04-20 Asta Pharma Aktiengesellschaft Ifosfamide lyophilisate and process for its preparation
US4879286A (en) 1987-01-28 1989-11-07 Lyphomed, Inc. Cyclophosphamide
US5223515A (en) 1988-08-18 1993-06-29 Takeda Chemical Industries, Ltd. Injectable solution containing a pyridyl methylsulfinylbenzimidazole
US5741523A (en) 1993-10-27 1998-04-21 Pharmacia & Upjohn Company Stabilized prostaglandin E1
AU706890B2 (en) 1994-01-24 1999-07-01 Procter & Gamble Company, The Process for solubilizing difficultly soluble pharmaceutical actives
US6261537B1 (en) 1996-10-28 2001-07-17 Nycomed Imaging As Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors
KR20010020611A (ko) 1997-07-01 2001-03-15 아테로제닉스, 인코포레이티드 항산화제에 의한 과증식질병 치료의 향상
ES2373864T3 (es) * 1998-04-20 2012-02-09 Eisai R&D Management Co., Ltd. Composición estabilizada que contiene un compuesto de tipo bencimidazol.
US6569402B1 (en) 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6686365B2 (en) * 2000-02-04 2004-02-03 Eli Lilly And Company Pharmaceutical composition
US6989139B2 (en) 2000-02-15 2006-01-24 Bristol-Myers Squibb Pharma Company Matrix metalloproteinase inhibitors
WO2001097860A2 (en) 2000-06-21 2001-12-27 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders for use in combination therapy
EP1296678A2 (en) 2000-06-21 2003-04-02 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals for use in combination therapy
EP1311292A2 (en) 2000-06-21 2003-05-21 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
AUPQ849900A0 (en) 2000-06-30 2000-07-27 Dbl Australia Pty Ltd. Injectable composition
WO2002004030A2 (en) 2000-07-06 2002-01-17 Bristol-Myers Squibb Pharma Company Stable radiopharmaceutical compositions
WO2002032427A1 (en) * 2000-10-20 2002-04-25 Galephar M/F Stable oral formulation containing benzimidazole derivative
US7252799B2 (en) * 2001-08-31 2007-08-07 Clearant, Inc. Methods for sterilizing preparations containing albumin
RU2344821C2 (ru) 2002-07-30 2009-01-27 Уайт Парентеральные композиции, содержащие гидроксиэфиры рапамицина
US20060035945A1 (en) 2003-05-30 2006-02-16 Giorgio Attardo Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases
US20060001597A1 (en) 2004-06-30 2006-01-05 Sokbom Han Image processing apparatus, systems and associated methods
EP1814544A4 (en) 2004-11-05 2009-12-02 Cephalon Inc CANCER TREATMENTS
SI1814517T1 (sl) 2004-11-22 2010-12-31 Venus Remedies Ltd Nevodna tekoäśa parentalna aceklofenak formulacija
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
US7872050B2 (en) 2005-03-14 2011-01-18 Yaupon Therapeutics Inc. Stabilized compositions of volatile alkylating agents and methods of using thereof
EP1909824B1 (en) 2005-04-08 2011-05-18 Amylin Pharmaceuticals, Inc. Pharmaceutical formulations comprising incretin peptide and aprotic polar solvent
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
CN1850048A (zh) 2006-06-09 2006-10-25 山东蓝金生物工程有限公司 一种含血管抑制剂的抗癌缓释注射剂
JPWO2008020584A1 (ja) 2006-08-14 2010-01-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 安定な凍結乾燥製剤
JP5721949B2 (ja) 2006-10-12 2015-05-20 アステックス、セラピューティックス、リミテッドAstex Therapeutics Limited 複合薬剤
US8414909B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
DE102007003184A1 (de) 2007-01-22 2008-07-24 Orlowski, Michael, Dr. Verfahren zur Beladung von strukturierten Oberflächen
US20090082416A1 (en) 2007-09-25 2009-03-26 Protia, Llc Deuterium-enriched bendamustine
AR072777A1 (es) * 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
CN104224703A (zh) * 2008-09-25 2014-12-24 赛福伦公司 苯达莫司汀的液体配制品
KR20110110293A (ko) * 2009-01-15 2011-10-06 세파론, 인코포레이티드 벤다무스틴 유리 염기의 신규 형태
AU2010217297A1 (en) * 2009-02-25 2011-10-20 Supratek Pharma, Inc. Bendamustine cyclopolysaccharide compositions
WO2010114770A1 (en) 2009-03-30 2010-10-07 Cerulean Pharma Inc. Polymer-agent conjugates, particles, compositions, and related methods of use
US20100273730A1 (en) 2009-04-27 2010-10-28 Innopharmax, Inc. Self-emulsifying pharmaceutical compositions of hydrophilic drugs and preparation thereof
JP2012525387A (ja) * 2009-04-28 2012-10-22 セファロン、インク. ベンダムスチンの経口製剤
CN101584668A (zh) 2009-06-19 2009-11-25 江苏奥赛康药业有限公司 盐酸苯达莫司汀冻干粉针剂
WO2010148288A2 (en) 2009-06-19 2010-12-23 Lyotropic Therapeutics, Inc. Pharmaceutical formulations with low aqueous levels of free unbound drug
US8389558B2 (en) * 2009-07-20 2013-03-05 Supratek Pharma Inc. Bendamustine amphiphilic anionic compositions
US20110015245A1 (en) * 2009-07-20 2011-01-20 Valery Alakhov Bendamustine amphiphilic cationic compositions
US7772274B1 (en) * 2009-10-19 2010-08-10 Scidose, Llc Docetaxel formulations with lipoic acid
WO2011094565A1 (en) 2010-01-28 2011-08-04 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
WO2011103150A2 (en) 2010-02-18 2011-08-25 Cephalon, Inc. Lyophilized preparations of bendamustine
JP5951600B2 (ja) 2010-05-21 2016-07-13 インフィニティー ファーマシューティカルズ, インコーポレイテッド キナーゼ調節のための、化合物、組成物および方法
US9655898B2 (en) 2010-07-28 2017-05-23 Eagle Pharmaceuticals, Inc. Pharmaceutical compositions containing pemetrexed having extended storage stability
US20130217888A1 (en) 2010-11-01 2013-08-22 Shailpa Medicare Limited Process for preparing bendamus tine hydrochloride monohydrate
JP2014516075A (ja) 2011-06-06 2014-07-07 シェブロン フィリップス ケミカル カンパニー エルピー 癌治療のためのメタロセン化合物の使用
EP3171171B1 (en) 2011-12-05 2018-07-18 Bio-rad Laboratories, Inc. Recombinant deamidated gliadin antigen
CN107353342B (zh) 2011-12-05 2021-08-10 X 博迪生物科学公司 PDGF受体β结合多肽
US20130210878A1 (en) 2012-01-24 2013-08-15 Innopharma, Inc. Bendamustine compositions and methods therefore
CA2864118A1 (en) 2012-02-14 2013-08-22 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
HRP20230276T1 (hr) 2012-03-20 2023-04-28 Eagle Pharmaceuticals, Inc. Tekući pripravci bendamustina za uporabu u postupku liječenja stanja koja reagiraju na bendamustin kod pacijenata kojima za primjenu trebaju reducirani volumeni
ES2972227T3 (es) 2012-03-20 2024-06-11 Eagle Pharmaceuticals Inc Formulaciones de bendamustina
JP6331468B2 (ja) 2014-02-27 2018-05-30 住友ベークライト株式会社 金属ラミネート用フィルム、ラミネート金属板および金属容器
US11707450B1 (en) * 2022-03-03 2023-07-25 Slayback Pharma Llc Stable pharmaceutical compositions of bendamustine

Similar Documents

Publication Publication Date Title
HRP20161771T4 (hr) Formulacije bendamustina
JP2015506989A5 (cg-RX-API-DMAC10.html)
ES2656901T3 (es) Una formulación estabilizada de pemetrexed
RU2016119746A (ru) Стабильный состав инсулина глулизин
WO2012015810A3 (en) Pharmaceutical compositions containing pemetrexed having extended storage stability
JP2010265321A5 (cg-RX-API-DMAC10.html)
RU2019118696A (ru) Фармацевтические композиции, содержащие инсулин
JP2015527402A5 (cg-RX-API-DMAC10.html)
BR112014009146A8 (pt) formulações de etanercepte estabilizadas com aminoácidos
AR092470A1 (es) Formulaciones acuosas estables de adalimumab
BR112015008186A2 (pt) formulação de um anticorpo estável e de baixa viscosidade
CO6311066A2 (es) Composiciones de alta densidad que contienen posaconazol y formulaciones que comprenden las mismas
EA201290128A1 (ru) Новые макроциклические ингибиторы репликации вируса гепатита с
BR112013026363A2 (pt) nanossuspensões de fármaco criodessecadas
UA109281C2 (uk) Фармацевтична композиція, яка містить похідне аміду або його фармацевтично прийнятну сіль
RU2016147362A (ru) Препараты жидкого концетрата циклофосфамида
MX2017010945A (es) Preparacion solida.
MX2015015356A (es) Formulacion estabilizada de pemetrexed.
JP2015514120A5 (cg-RX-API-DMAC10.html)
ECSP12011699A (es) Tableta
JP2016503058A5 (cg-RX-API-DMAC10.html)
EA201591246A1 (ru) Раствор для сохранения сосудистых трубок
AR090592A1 (es) Sales de 5-[(1r)-2-({2-[4-(2,2-difluoro-2-feniletoxi)fenil]etil}amino)-1-hidroxietil]-8-hidroxiquinolin-2(1h)-ona
EA201170287A1 (ru) Фармацевтические композиции и способы их стабилизации
RU2019119405A (ru) Лиофилизированные фармацевтические композиции далбаванцина